Empiget (manufactured by Getz Pharma) is an oral antihyperglycemic medication containing empagliflozin, a potent and selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is the primary transport protein located in the proximal renal tubules of the kidneys, responsible for reabsorbing approximately 90% of filtered glucose back into the bloodstream.
By selectively inhibiting SGLT2, Empiget prevents renal reabsorption of glucose, lowering the renal threshold and promoting urinary glucose excretion (glycosuria). In addition to lowering blood glucose levels without stimulating insulin secretion, this osmotic diuresis and natriuresis lead to modest reductions in body weight, blood pressure, and intraglomerular pressure, providing substantial cardiovascular and renal protective benefits.
Primary Medical Indications
Empiget is indicated in adult patients for multiple major cardiometabolic and renal conditions:
-
Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults and children (aged 10 years and older) with type 2 diabetes.
-
Cardiovascular Risk Reduction: To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
-
Heart Failure (HF): To reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients across the full spectrum of left ventricular ejection fraction (HFrEF and HFpEF).
-
Chronic Kidney Disease (CKD): To reduce the risk of sustained eGFR decline, end-stage kidney disease (ESKD), cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
Key Product Specifications & Dosing Forms
| Feature | Specification |
| Active Ingredient | Empagliflozin |
| Pharmacological Class | Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor |
| Available Formulations | Film-coated oral tablets |
| Common Strengths | 10 mg, 25 mg tablets |
| Standard Dosage | 10 mg once daily, taken in the morning with or without food. May be increased to 25 mg once daily if additional glycemic control is required |
| Renal Threshold | Glycemic efficacy decreases when eGFR is less than 30 mL/min/1.73 $\text{m}^2$; however, cardiorenal benefits extend down to eGFR levels of 20 mL/min/1.73 $\text{m}^2$ |
Critical Safety Guidelines & Precautions
-
Euglycemic Diabetic Ketoacidosis (DKA): SGLT2 inhibitors can cause DKA, a life-threatening emergency that may present with normal or only moderately elevated blood glucose levels (less than 250 mg/dL). Withhold Empiget immediately in patients presenting with severe metabolic acidosis, nausea, vomiting, or abdominal pain. Discontinue temporarily prior to major surgical procedures.
-
Genitourinary Mycotic Infections: Increased urinary glucose excretion increases susceptibility to vulvovaginal candidiasis in females and mycotic balanitis in males.
-
Fournier’s Gangrene (Necrotizing Fasciitis): A rare but severe, life-threatening bacterial infection of the perineal tissues reported in both men and women taking SGLT2 inhibitors. Prompt medical evaluation is required if pain, tenderness, erythema, or swelling occurs in the genital area alongside fever or malaise.
-
Volume Depletion & Hypotension: Osmotic diuresis can lead to intravascular volume contraction and symptomatic hypotension, especially in elderly patients, those on loop diuretics, or individuals with impaired renal function.
-
Urinary Tract Infections: Serious UTIs, including urosepsis and pyelonephritis requiring hospitalization, have been reported.
-
Not for Type 1 Diabetes: Empiget is not indicated for type 1 diabetes mellitus due to an increased risk of diabetic ketoacidosis.
Reviews
There are no reviews yet.